You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR SORBITOL 3% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SORBITOL 3% IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000159 ↗ Sorbinil Retinopathy Trial (SRT) Completed National Eye Institute (NEI) Phase 3 1983-08-01 To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00121433 ↗ Leptin and Endothelial Function Completed Amgen Phase 4 2004-09-01 The purpose of this trial was to determine if injections of leptin would improve vascular function in normal-weight, healthy volunteers.
NCT00121433 ↗ Leptin and Endothelial Function Completed University of Michigan Phase 4 2004-09-01 The purpose of this trial was to determine if injections of leptin would improve vascular function in normal-weight, healthy volunteers.
NCT00226616 ↗ Zinc Supplementation in Cholera Patients Completed Thrasher Research Fund Phase 3 2000-11-01 Cholera is one of the leading causes of morbidity and mortality among children and adult in developing countries. We will evaluate the effect of supplementation of zinc on reduction of duration and severity of cholera. Since cholera is primarily a disease of older children and adults, we intend to study the effects of zinc supplementation among children of 3 to 14 years of age, whose initial stool weight will be >4ml/kg/hour in 1st 6 hours and dark field examination is positive. 90 subjects in each group hospitalized with cholera with diarrhea for less than 24 hours will be selected. After inclusion in the study, informed consent will be obtained from guardian explaining the full procedure in the hospital. The subjects will be randomized to receive either zinc or placebo until diarrhea resolves. History of illness and baseline information will be collected in the hospital through interview, which may take duration of 10 minutes.After 6 hours of initial rehydration, fluid balance study will be carried out on all subjects until diarrhea resolves. 1 ml (1/4 teaspoonful) of blood sample will be taken to assess serum zinc level on admission after initial hydration and will be repeated on the day of recovery. This procedure carries a small risk of infection if not done under sanitary conditions; however, we will maintain proper sanitation, so there is no risk in the procedures. There is no potential risk in this study.20mg elemental Zinc will be given daily in 2 divided doses till cholera resolves. Both groups will receive syrup or tablet Erythromycin 50mg/kg/24 in 4 divided doses for 3 days. Oral rehydration solution/intravenous acetate fluid will be used for rehydration. Daily body weight will be taken and stool will be sent for C/S until the day of recovery or 5 days. Zinc loss in stool will be seen in 20% of random stool samples. Information obtained from history and the laboratory investigations of subject will be kept strictly confidential and no one other than the investigators of this study and the Ethics Committee of this Centre will/ has access to the information. The study will benefit the patients as study physician will do close observation, examination and will take care frequently, as research staff will monitor systematic progress and take necessary action. Study micronutrient (zinc) is shown to have benefit in children in acute diarrhea. If the results of the study is positive, it will benefit the patients in their treatment during this study and thereafter. The data will be analyzed for clinical effects of zinc on diarrhea.The study will help to improve the treatment strategy of cholera in children. The study will use hospital records, which will be returned after completion of the study. Stool, urine and 1 ml (1/4 teaspoonful) of venous blood will be taken to assess serum zinc level.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SORBITOL 3% IN PLASTIC CONTAINER

Condition Name

Condition Name for SORBITOL 3% IN PLASTIC CONTAINER
Intervention Trials
Severe Mental Illness 2
Constipation 2
Intoxication 2
Sepsis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SORBITOL 3% IN PLASTIC CONTAINER
Intervention Trials
Tooth Diseases 3
Nerve Compression Syndromes 3
Hereditary Sensory and Motor Neuropathy 3
Charcot-Marie-Tooth Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SORBITOL 3% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for SORBITOL 3% IN PLASTIC CONTAINER
Location Trials
United States 27
China 5
Turkey 4
Moldova, Republic of 4
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SORBITOL 3% IN PLASTIC CONTAINER
Location Trials
New York 3
Kansas 3
California 3
Ohio 2
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SORBITOL 3% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for SORBITOL 3% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 10
Phase 3 6
Phase 2/Phase 3 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SORBITOL 3% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Completed 16
Recruiting 9
Unknown status 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SORBITOL 3% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for SORBITOL 3% IN PLASTIC CONTAINER
Sponsor Trials
Yuria-Pharm 4
Sahlgrenska University Hospital, Sweden 3
ScandiBio Therapeutics AB 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SORBITOL 3% IN PLASTIC CONTAINER
Sponsor Trials
Other 48
Industry 19
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.